IL2 and ovarian cancer: Individuals with ovarian cancer were divided into two cohorts as eight of them underwent T cell therapy with high-dose IL-2 (cohort I) and six underwent pre-treatment with dual-specific T cells scheduled to be followed by allogeneic peripheral blood mononuclear cells (PBMCs) for immunization (cohort II) (97).